Antiangiogenic gene therapy for @entity157 using XXXX gene.

@entity1 @entity558 @entity7 @entity5 @entity19 @entity21114 @entity9294 @entity157 @entity43312 @entity13191
Recent studies have reported that antiangiogenic gene delivery into @entity5 cells inhibits growth of certain @entity5 in vivo. @entity157 ( @entity157 ) is a hypervascular @entity5 , and antiangiogenic gene therapy might be suitable for @entity157 . In the present study, we investigated the antiangiogenic effects of @entity43312 gene transduction into @entity157 both in vitro and in vivo. @entity43312 gene was cloned into a pSecTag2B @entity1 expression vector to construct pSecTag2B-ANG. pSecTag2B or pSecTag2B-ANG were transfected into an @entity157 cell line, @entity9294 /PRF/5, and then stable transfectants were obtained by @entity21114 selection. pSecTag2B or pSecTag2B-ANG transfection did not alter the expression of @entity7 ( @entity7 ), a potent angiogenic stimulator, or @entity13191 ( @entity13191 ), an angiogenic inhibitor, in @entity9294 /PRF/5 cells. However, conditioned media (CM) derived from pSecTag2B-ANG-transfected @entity9294 /PRF/5 cells (CM-ANG) suppressed the proliferation and migration of @entity1 umbilical vein endothelial cells (HUVEC) by 35% and 50%, respectively, relative to their effects on nontransfected cells. In in vivo experiments, pSecTag2B-ANG stable transfected (CM-Mock) and nontransfected cells ( @entity558 ) were mixed at various proportions and the mixed cells were subcutaneously implanted into athymic @entity19 . Suppression of @entity5 growth was noted in @entity19 implanted with @entity43312 gene-transfected cells, and such suppression was proportional with the percentage of transfected cells. Analysis of the vascular density in these @entity5 showed that the @entity5 growth suppression effect of @entity43312 gene correlated with suppression of @entity5 vascularity. In conclusion, antiangiogenic gene therapy using @entity43312 gene is potentially suitable for the treatment of @entity1 with @entity157 .
